Patents by Inventor Patrick Sosnay

Patrick Sosnay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATMENT FOR CYSTIC FIBROSIS
    Publication number: 20250288563
    Abstract: This application describes methods of treating cystic fibrosis or a CFTR mediated disease comprising administering Compound I or a pharmaceutically acceptable salt thereof. The application also describes pharmaceutical compositions comprising Compound I or a pharmaceutically acceptable salt thereof and optionally comprising one or more additional CFTR modulating agents.
    Type: Application
    Filed: November 27, 2024
    Publication date: September 18, 2025
    Inventors: Bartlomiej Borek, Weichao George Chen, Rudy Gunawan, Eric Haseltine, Nitin Nair, Porntula Panorchan, Patrick Sosnay
  • Methods of treatment for cystic fibrosis
    Patent number: 12186306
    Abstract: This application describes methods of treating cystic fibrosis or a CFTR mediated disease comprising administering Compound I or a pharmaceutically acceptable salt thereof. The application also describes pharmaceutical compositions comprising Compound I or a pharmaceutically acceptable salt thereof and optionally comprising one or more additional CFTR modulating agents.
    Type: Grant
    Filed: December 9, 2021
    Date of Patent: January 7, 2025
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Bartlomiej Borek, Weichao George Chen, Rudy Gunawan, Eric Haseltine, Nitin Nair, Porntula Panorchan, Patrick Sosnay
  • METHODS OF TREATMENT FOR CYSTIC FIBROSIS
    Publication number: 20220184049
    Abstract: This application describes methods of treating cystic fibrosis or a CFTR mediated disease comprising administering Compound I or a pharmaceutically acceptable salt thereof. The application also describes pharmaceutical compositions comprising Compound I or a pharmaceutically acceptable salt thereof and optionally comprising one or more additional CFTR modulating agents.
    Type: Application
    Filed: December 9, 2021
    Publication date: June 16, 2022
    Inventors: Bartlomiej Borek, Weichao George Chen, Rudy Gunawan, Eric Haseltine, Nitin Nair, Porntula Panorchan, Patrick Sosnay